Navigation Links
ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
Date:12/6/2011

subcutaneous dispersion and absorption of these drugs. Molecules as large as 200 nanometers may pass freely through the extracellular matrix, which recovers its normal density within approximately 24 hours, leading to a drug delivery platform which does not permanently alter the architecture of the skin. The principal focus of Halozyme's Enhanze technology platform is the use of rHuPH20 to facilitate subcutaneous administration for large molecule biological therapeutics, some of which currently require intravenous administration.

About Hereditary Angioedema (HAE)

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unregulated, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,500 people with HAE in the United States and at least 10,000 people in the European Union.

For more information on HAE, visit the HAEi's (International Patient Organization for C1 Inhibitor Deficiencies) website at www.haei.org and the U.S. HAE Association's website at: www.haea.org.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet med
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ViroPharma to Participate in Two November Healthcare Investor Conferences
2. ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline
3. ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
4. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
5. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
6. ViroPharma Announces Additional Securities Repurchase Program
7. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
8. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
9. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
10. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
11. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  A prospective ... Sweden has validated the performance ... platforms and has associated volumetrically assessed breast density ... Cancer Epidemiology, Biomarkers & Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), ... a tool for widespread breast cancer risk assessment," ...
(Date:7/28/2014)... , July 28, 2014  TNI BioTech, ... biopharmaceutical company focused on the development, marketing and ... has filed definitive proxy materials with the Securities ... Annual Meeting of Shareholders to be held on ... Standard Time. The record date for determining those ...
(Date:7/28/2014)...  ResMed (NYSE: RMD ), an innovator ... sleep-disordered breathing and other chronic respiratory conditions, has won ... against Taiwanese medical device manufacturer APEX Medical Corp. (APEX), ... 210 and 220 masks.  The judgment was entered by ... , is appealable, and applies throughout Germany.  ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2
...  Althea Technologies, Inc., a leading provider of development ... the appointment of Dr. Kristin DeFife as Director, ... and Marketing. (Logo:  http://photos.prnewswire.com/prnh/20020925/LAW010LOGO ... will be responsible for leading Althea,s microbial biologics ...
... May 1, 2012  Intrepid Investment Bankers LLC ("Intrepid"), ... announced the sale of Newport Medical Instruments, Inc. ... closed on May 1, 2012.  Intrepid acted as ... with the transaction.  (Logo:  ...
Cached Medicine Technology:Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing 2Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing 3Intrepid Investment Bankers LLC Advises Newport Medical Instruments, Inc. in its Sale to Covidien plc 2
(Date:7/28/2014)... Medicine (BUSM) report variants in a new gene, PLXNA4, ... (AD). The discovery of this novel genetic association may ... specifically. These findings appear in the Annals of ... dementia affecting 5.4 million Americans including 13 percent of ... percent of people age 85 and older. Genetic factors ...
(Date:7/28/2014)... University of Texas Health Science Center at San Antonio, the ... of pills that cures 9 of 10 hepatitis C patients. ... or without ribavirin, cured 93 percent of patients in 12 ... study published today in The Lancet . , ... Lawitz, M.D., clinical professor in the School of Medicine at ...
(Date:7/28/2014)... The Wireline Services Market in Europe report defines and ... forecast of revenue. The Wireline services market in Europe is ... $2.4 billion by 2019, at a CAGR of 11.2%, for ... Wireline Services Market in Europe report, to get an idea ... of the segmentation in the European Wireline Services market, and ...
(Date:7/28/2014)... America Carotenoids & Antioxidants Market report defines and segments the ... forecast of revenue. This market is estimated to grow from ... at a CAGR of 7.1% from 2013 to 2018. , ... Antioxidants Market report to get an idea of the in-depth ... in the market, and is supported by various tables and ...
(Date:7/28/2014)... -- A common inflammatory muscle disorder that causes ... the risk for heart attack and stroke, ... that patients with polymyalgia rheumatica are more likely ... the blood vessels. Doctors should carefully manage the ... to reduce their risk for complications, the study ...
Breaking Medicine News(10 mins):Health News:Researchers identify potential biomarker for AD 2Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Inflammatory Muscle Disorder May Raise Risk for Heart Attack, Stroke 2
... a small percentage of alcoholics develop cirrhosis of the ... (ALD); the reason why all alcoholics do not develop ... from Spain, that includes original work and a meta-analysis, ... (GST) relate to the risk of developing ALD among ...
... the strength of uterine contractions in diabetic pregnant women is ... emergency caesarean birth. In the past 10 ... by approximately 50%. There has, however, been very little ... a normal vaginal delivery. Scientists at the ...
... in the artery begins to regrow. In the long term, ... A common cause of arterial injuries is the clearing ... a heart attack. "Initially the artery is opened up, ... of further heart attacks." In animal experiments, the research ...
... HealthDay Reporter , MONDAY, Dec. 5 (HealthDay News) -- A man,s ... his body weight, a novel finding that runs counter to conventional ... journal Circulation finds that improving or even just maintaining ... your body weight has stayed the same or even gone up. ...
... -- Health care coverage increased dramatically in parts of ... interventions were implemented to improve access to health care, ... new research by Brown University sociologist Susan E. Short ... findings appear in the December issue of Health ...
... of Clinical Oncology (ASCO) today released Clinical Cancer Advances ... independent review of the advances in cancer research that ... year. The report also identifies the most promising ... where the future of cancer care is heading. ...
Cached Medicine News:Health News:Poorly contracting uterus in diabetic women increases risk of caesarean birth 2Health News:Stopping dangerous cell regrowth reduces risk of further heart attacks 2Health News:Fitness May Lower Death Risk Even Without Weight Loss 2Health News:Fitness May Lower Death Risk Even Without Weight Loss 3Health News:Chinese health coverage increases with new government efforts 2Health News:Chinese health coverage increases with new government efforts 3Health News:American Society of Clinical Oncology issues annual report on progress against cancer 2Health News:American Society of Clinical Oncology issues annual report on progress against cancer 3
Slitlamp-mounted contact tonometer for precision tonometry (corneal thickness independent)...
... from the simplicity and ease of the ... history and reputation for accuracy, reliability and ... between rooms. With no wires to ... Retinomax has full measurement range and advanced ...
... fourth generation septal repair implant. It differs ... a unique self-centering mechanism, fabricated from a ... attached to alternating sides of the umbrella ... mechanism which assists to centrally locate the ...
Introducing the Guidant HEARTSTRING Proximal Seal System. A surgically intuitive system that meets the challenge of clampless hemostasis with a design that is elegant in its simplicity and profound i...
Medicine Products: